Nemaura Medical (OTCMKTS:NMRD – Get Free Report) is projected to post its resultson Tuesday, November 17th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $0.20 million for the quarter.
Nemaura Medical Price Performance
Shares of Nemaura Medical stock opened at $0.00 on Tuesday. The stock has a market cap of $4,035.20, a P/E ratio of -0.00 and a beta of 0.38. Nemaura Medical has a 12-month low of $0.00 and a 12-month high of $0.05.
Nemaura Medical Company Profile
Nemaura Medical, Inc is a medical technology company focused on developing wearable solutions for diabetes and metabolic health monitoring. Its principal product is SugarBEAT, a non-invasive glucose monitoring system designed to provide continuous or periodic glucose readings without the need for traditional finger-stick testing.
SugarBEAT is designed to use a disposable skin patch, a reusable sensor transmitter and a software application to collect and display glucose information. The company has also described applications for the technology in diabetes management, prediabetes monitoring and broader wellness programs.
Nemaura Medical has pursued regulatory clearances and commercial opportunities in international markets, including the United Kingdom and Europe.
Further Reading
- Five stocks we like better than Nemaura Medical
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
